抗人 KLK9 抗体对
01AB02428
Kallikrein related peptidase 9 (KLK9) is a glycosylated serine protease belonging to the kallikrein family, characterized by a chymotrypsin-like structure and a strong preference for cleaving peptide bonds after tyrosine residues at the P1 position, rather than phenylalanine. KLK9 is synthesized as a preproenzyme and undergoes proteolytic processing to become active, with its enzymatic activity enhanced by magnesium and calcium ions and reversibly inhibited by zinc ions. It is primarily expressed in tissues such as thymus, testis, spinal cord, cerebellum, trachea, mammary gland, prostate, brain, salivary gland, ovary, and skin. KLK9 is inhibited in vitro by various natural and synthetic protease inhibitors and has been shown to interact with substrates like KLK10 and midkine. Clinically, KLK9 is regulated by steroid hormones in ovarian and breast cancer cell lines and is considered a potential prognostic marker for early-stage ovarian and breast cancer patients.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- KLK9
- 蛋白别名
- kallikrein related peptidase 9; KLK9
- UniProt
- Q9UKQ9
- 物种
- Human
产品详情
- 靶点名称
- KLK9
- 蛋白名称
- kallikrein related peptidase 9
- 蛋白别名
- Kallikrein-9; Kallikrein-like protein 3; KLK-L3
- 靶点基因名
- KLK9
- UniProt
- Q9UKQ9
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Kallikrein related peptidase 9 (KLK9) is a glycosylated serine protease belonging to the kallikrein family, characterized by a chymotrypsin-like structure and a strong preference for cleaving peptide bonds after tyrosine residues at the P1 position, rather than phenylalanine. KLK9 is synthesized as a preproenzyme and undergoes proteolytic processing to become active, with its enzymatic activity enhanced by magnesium and calcium ions and reversibly inhibited by zinc ions. It is primarily expressed in tissues such as thymus, testis, spinal cord, cerebellum, trachea, mammary gland, prostate, brain, salivary gland, ovary, and skin. KLK9 is inhibited in vitro by various natural and synthetic protease inhibitors and has been shown to interact with substrates like KLK10 and midkine. Clinically, KLK9 is regulated by steroid hormones in ovarian and breast cancer cell lines and is considered a potential prognostic marker for early-stage ovarian and breast cancer patients.